IXICO PLC (LON:IXI) said it has entered a five year collaboration with the Friedreich’s Ataxia Research Alliance (FARA) to become a member of the TRACK-FA neuroimaging consortium, focused on exploring novel imaging markers for Friedreich’s Ataxia (FA).
FA is a rare genetic disease that causes difficulty walking, a loss of sensation in the arms and legs and impaired speech. The disease can also damage parts of the brain and spinal cord and affect the heart.
IXICO, an AIM-listed neuroscience data analytics specialist, said it will support the consortium to implement novel analysis algorithms with the aim of providing a trial-ready imaging solution for FA clinical trials.
The company added that it will be an industry member and stakeholder in the consortium and will work alongside academic partners with expertise in neuroimaging and conducting clinical research in FA including Monash University in Australia), the University of Minnesota and Aachen University in Germany.
IXICO said while the contract will not have a significant impact of management expectations for its performance this year, it will contribute to its “already strong year-end order book”.
“This new consortium will help to accelerate the quest for new treatments for Friedreich’s Ataxia by bringing together some of the leading researchers in the field from both academia and industry with the specific goal of developing new tools to better understand and characterise this debilitating disease”, IXICO’s senior vice president for science and innovation Robin Wolz said in a statement.
“IXICO will bring its expertise in neuroimaging and AI to support the development and validation of new biomarkers which in turn will help to identify the most promising treatments and bring these to patients sooner”, Wolz added.